Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders.

By Douglas B. Johnson, R. Sullivan, P. Ott, M. Carlino, N. Khushalani, Fei Ye, A. Guminski, I. Puzanov, D. Lawrence, E. Buchbinder and 11 more. JAMA Oncology, 2016

607 citations recorded by the source corpus.

Subfields: Immunology, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/a04e4866702fc29a4ce67aa667a779573f4f5bae

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. C. Robert
2. Antoni Ribas

In Molecular Biology

1. C. Robert

In Oncology

1. Antoni Ribas
2. C. Robert
3. J. Haanen
4. J. Larkin
5. K. Kerr
6. S. Peters
7. F. Carbonnel
8. Georgina V. Long

Citations in the corpus

• Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2017, background): “Two out of six patients with CD or UC had ipilimumab-induced colitis or a relapse of UC or CD [39].”
• Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab (2016, background): “Indeed, recently, we reported the safety and activity of ipilimumab in 30 patients with a range of preexisting autoimmune disorders [11].”
• Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018, background): “Two out of six patients with CD or UC had ipilimumab-induced colitis or a relapse of UC or CD [39].”